2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
13
Neoplasms
12
Brain Neoplasms
6
Prostatic Neoplasms
5
Neoplasm Metastasis
4
Lung Neoplasms
4
Sarcoma
3
Multiple Myeloma
3
Melanoma
3
Glioblastoma
3
Gastrointestinal Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Thymus Neoplasms
2
Stomach Neoplasms
2
Sarcoma, Synovial
2
Rectal Neoplasms
2
Pain
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neuroendocrine Tumors
2
Nasopharyngeal Carcinoma
2
Mesothelioma
2
Liposarcoma
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Glioma
2
Fatigue
2
Colorectal Neoplasms
2
Interventions
Doxorubicin
9
Imatinib Mesylate
6
pazopanib
4
Ifosfamide
4
Radiotherapy
3
Gemcitabine
3
Docetaxel
3
pembrolizumab
2
Radiation
2
Neoadjuvant Therapy
2
Mohs Surgery
2
Biopsy
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
selinexor
1
saracatinib
1
sapanisertib
1
ribociclib
1
peposertib
1
liposomal doxorubicin
1
indolepropanol phosphate
1
envafolimab
1
cixutumumab
1
brigimadlin
1
avelumab
1
X-Rays
1
Watchful Waiting
1
TTI-621
1
Sunitinib
1
Specimen Handling
1
Razoxane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dermatofibrosarcoma
×
Quality of Life
×
Clear all
NCT07169344
2026-01-28
PROSARC-1
Oslo University Hospital
Phase 2
Recruiting
110 enrolled